

LEFLUMED-10 TABLETS

Leflunomide I.P. 10 mg

"Trusted DMARD for Long-Term Arthritis Management"

Marketed by: Human Orthocare

A Subsidiary of Human Biolife India Pvt. Ltd.

www.humanorthocare.com





Product Overview



Composition (per tablet):

3 Leflunomide I.P. – 10 mg

Key Features:

- Immunomodulatory **DMARD** for rheumatoid & psoriatic arthritis
- Slows disease progression & prevents joint damage
- Effective as monotherapy or in combination with methotrexate
- Improves long-term patient outcomes

Leflumed-10 represents a breakthrough in diseasemodifying antirheumatic drug therapy, offering patients comprehensive protection against progressive joint damage whilst maintaining excellent tolerability profiles.

Mechanism of Action



Enzyme Inhibition

Inhibits dihydroorotate dehydrogenase - reduces pyrimidine synthesis



Lymphocyte Control

Prevents proliferation of activated T & B lymphocytes




Inflammation Reduction

Decreases autoantibody production & inflammation



Clinical Result

Reduced joint damage, inflammation & disease activity







Clinical Indications

Leflumed-10 Tablets are clinically recommended for comprehensive management of autoimmune arthritic conditions:

Rheumatoid Arthritis (RA)

Primary indication for disease modification and joint preservation

Psoriatic Arthritis

Effective control of both skin and joint manifestations

Juvenile Idiopathic Arthritis


Off-label use under specialist supervision

Other Autoimmune Disorders

As per physician guidance and clinical assessment

Clinical Advantages





Key Benefits of Leflumed-10:

Disease-Modifying Action

Actively slows arthritis progression rather than merely masking symptoms

Triple Therapeutic Effect

Provides pain relief + inflammation control + joint protection

Patient Compliance

Oral once-daily dosing enhances adherence to treatment

Combination Flexibility

Effective as monotherapy or in MTX combination

Superior Tolerability

Better tolerated than long-term high-dose corticosteroids




Comparison with Other DMARDs

Comprehensive comparative analysis of disease-modifying antirheumatic drugs demonstrates Leflumed-10's clinical positioning:

Parameter	Leflumed-10 (Leflunomide)	Methotrexate	Hydroxychloroquine
Onset of Action	4–6 weeks	4–6 weeks	6–12 weeks
Immunosuppressive Power	√Strong	√Strong	1 Mild
Combination Use	√ Yes (with MTX, HCQ)	√Yes	√Yes
Hepatic Safety	⚠ Monitor LFTs	<u>Monitor</u>	√Safer
Long-Term Efficacy	√ High	√ High	1 Limited

Dosage & Administration





1

Standard Dosage

10-20 mg once daily

Dosage may be adjusted according to disease severity and individual patient profile

2

Important Considerations

Long half-life → therapeutic effects persist even after discontinuation

3

Monitoring Requirements


Regular monitoring of liver function & blood counts is essential

Clinical Note: The extended half-life of leflunomide requires careful consideration of dosing intervals and potential drug interactions.

Safety & Tolerability Profile


Common Side Effects:

- Diarrhoea, nausea, abdominal pain
- Mild hair loss, rash
- Rare: hepatotoxicity, cytopenia, hypertension



Patient Tolerance

Well-tolerated in clinical studies



Discontinuation Rate

Due to adverse effects



Contraindications:

Hepatic Impairment


Severe hepatic dysfunction

Pregnancy & Lactation

Teratogenic potential requires avoidance

Immunocompromised Patients

Additional immunosuppression contraindicated





Why Prescribe Leflumed-10?

The **Doctor's Choice** for Comprehensive Arthritis Management



Potent DMARD Action

Strong immunosuppressive action with proven disease-modifying capabilities



Patient-Friendly Dosing

Oral, once-daily convenient dosing enhances compliance



Dual Indication Coverage

Effective in both **RA & psoriatic arthritis** management



Long-Term Benefits

Improves long-term outcomes & prevents progressive disability



Trusted Quality

Backed by **Human Orthocare** pharmaceutical excellence





Contact Us

Step into care that moves you forward.

Use with clinical discretion, especially in high-risk orthopedic conditions.

HumAn Orthocare – A Subsidiary of Human Biolife India Pvt. Ltd.

For medical queries or collaboration:



www.humanorthocare.com